Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma

Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma

The need for improved healthcare infrastructure for extranodal NK/T-cell lymphoma in Latin America

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results

SABCS 2024: Highlights in breast cancer genomic testing

Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r CLL

Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC

Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma